Trial Profile
Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2023
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 22 Feb 2023 Results comparing the PK parameters of sofosbuvir/velpatasvir (SOF/VEL) in pregnant versus nonpregnant women, and to assess delivery outcomes and viral response, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 Planned End Date changed from 1 Feb 2020 to 1 Jan 2020.